First COVID-19 Vaccine Doses To Go To Health Workers, Say CDC Advisers

November 5th, 2020

Medical staff members treat a patient seriously ill with COVID-19 in the intensive care unit of United Memorial Medical Center on Oct. 31 in Houston. Experts say immunizing health workers first, once a COVID-19 vaccine’s available, is best to curb deaths and stop transmission.

Health care workers will almost certainly get the first doses of COVID-19 vaccine in the U.S. when one is approved, according to Dr. José Romero, head of the committee that develops evidence-based immunization guidelines for the Centers for Disease Control and Prevention.

That’s a decision based on the science of what will quell the pandemic fastest. “It’s not just the doctors and nurses that are interacting with patients, but also the support personnel that help,” Romero said in an interview Thursday with NPR. “It could include those persons that are delivering food, or maintenance people that could come in contact with them,” so they can protect themselves and patients from the virus, and stay healthy to keep the U.S. health care system running.

Romero chairs the Advisory Committee on Immunization Practices, or ACIP, a longstanding CDC advisory group that includes 15 voting members, plus other vaccination experts who weigh in.

Once the Food and Drug Administration judges a COVID-19 vaccine to be safe, effective and authorized for use, ACIP will make rapid recommendations to the CDC on how a COVID-19 vaccine should be used and who should get the first shots.

“We anticipate having some vaccine for the high-risk individuals — health care providers — sometime in December or early January,” Romero told NPR’s Mary Louise Kelly on All Things Considered. “And then more and more vaccine will be rolled out.”

The committee’s goals for deploying a COVID-19 vaccine are to “decrease death and serious disease as much as possible” to keep society functioning and to reduce the burden of health disparities, according to the CDC website.

Beyond health care workers, three additional groups are considered by ACIP to be especially vulnerable to COVID-19, based on their exposure or susceptibility to the virus: essential workers, people age 65 and older, and anyone with underlying medical conditions associated with getting seriously ill from COVID-19.

The order of which of those groups would get their first doses — and when — may depend on the particular characteristics of whichever vaccine or vaccines are ultimately approved by the FDA. Such characteristics might include whether a particular vaccine has been demonstrated to be effective in older people, safe in people with conditions such as cancer or heart disease, or safe during a pregnancy. It’s too soon to say which of the possible vaccines might be most suitable for which groups of people, he said.

“We haven’t seen the data yet,” Romero said, because vaccine clinical trials are still underway.

While they wait for that data, the committee members have been reviewing possible scenarios, using tools such as CDC computer models that project the number of lives that would be saved, based on assumptions about how effective a vaccine is and how many people get immunized.

By reviewing these potential outcomes now, the committee hopes to be able to move quickly once a vaccine is authorized. “There will be an emergency meeting of ACIP within 24 to 48 hours after the FDA has made [its] recommendations on the approval,” Romero said.

At that meeting, ACIP members will vote on recommendations on dosage and a list of priority groups, which will become part of public health guidance issued by the CDC to states and territories, on how to vaccinate populations effectively against disease. Those guidelines will also signal the federal government to start shipping vaccine vials out to hospitals and vaccination sites across the country.

“We want shots in arms within 24 hours [of ACIP’s recommendations],” Paul Mango, a top official with the U.S. Department of Health and Human Services, told reporters in a call last month.

The urgency with which the committee intends to move is motivated by the intention to save lives, Romero said — and is free from political influence.

“I’ve had no contact with the [Trump] administration or with pharmaceutical companies influencing my decision,” he said. “No shortcuts should be taken for this vaccine, and it should be scrutinized the same way we would advise any other vaccine for prevention of infectious diseases.”

State health officials are responsible for determining where vaccines should be distributed within their borders. Romero plays a key role regarding that distribution in Arkansas, where he also is health secretary.

“We’ve identified the top 10 hospitals to receive the initial allotment of vaccine,” he said. “And as the vaccine becomes more available, we’ll add more and more hospitals to that list.”